|Day Low/High||40.48 / 41.09|
|52 Wk Low/High||31.43 / 48.25|
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
We've seen some high quarterly dividend increases of late, so let's pick out the crème of the crop.
Our latest analysis and trading strategy for the the big pharma stock.
Analysts from the independent research firm review their picks from last year and share their new favorites.
Shares of the pharma company have broken out on our Point and Figure chart.
These stocks are priced for total imperfection. That's just what you want.
The long-term technical view of GSK is very bullish.
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
If we can advance without China then who the heck knows where we can go with it.
These themes are working despite the turmoil in Washington and slowing global growth.
So far 2019 is proving to be a year where things have a habit of working out right.
One of pharma's biggest CEO's talks M&A action on the exchange.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Strong balance sheet and royalties are big positives for Innoviva.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.